KLOW 80mg | Buy Research-Grade KLOW in Europe | ≥99% Purity

KLOW 80mg is a research-grade oral tablet formulation combining Ketoprofen and Omeprazole, available to buy in Europe for laboratory research into NSAID pharmacology, COX enzyme inhibition, prostaglandin biology, and gastrointestinal protection mechanisms in NSAID co-administration models.

Laboratories and research institutions across the EU can order verified, research-grade KLOW 80mg with fast international dispatch to Europe, full batch documentation, and verified purity confirmed by HPLC and analytical testing.

✅ Verified Purity — Analytically Tested

✅ Batch-Specific Certificate of Analysis (CoA)

✅ Oral Tablet Formulation | GMP Manufactured

✅ Fast Dispatch to EU & Europe | Tracked Shipping

What is KLOW 80mg?

KLOW 80mg is a combination research formulation containing Ketoprofen — a potent, non-selective non-steroidal anti-inflammatory drug (NSAID) — and Omeprazole — a proton pump inhibitor (PPI) — combined in a single oral tablet to enable research into NSAID pharmacology alongside the gastrointestinal protection strategies used to mitigate NSAID-associated gastric injury.

Ketoprofen is a propionic acid class NSAID that inhibits both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes — the enzymes responsible for converting arachidonic acid into prostaglandins, thromboxanes, and prostacyclins that mediate inflammation, pain signalling, fever, and platelet aggregation. Its non-selective COX inhibition profile produces potent anti-inflammatory and analgesic effects while also reducing the gastroprotective prostaglandins normally produced by COX-1 activity in gastric mucosa — a mechanistic basis for NSAID-associated gastric injury that makes gastrointestinal protection research directly relevant to ketoprofen pharmacology.

Omeprazole is a benzimidazole PPI that irreversibly inhibits the H+/K+-ATPase proton pump in gastric parietal cells — reducing gastric acid secretion and raising intragastric pH. Its inclusion in the KLOW formulation mirrors the standard clinical and pre-clinical strategy of co-administering a PPI with NSAIDs to reduce gastric acid-mediated mucosal injury in the context of COX-1-mediated gastroprotective prostaglandin suppression.

Together, the KLOW combination provides a research tool for studying NSAID-PPI co-administration pharmacology — an area of significant interest in gastrointestinal protection research, drug interaction biology, and the mechanistic investigation of NSAID-associated gastric injury and its mitigation.

What Does KLOW 80mg Do in Research?

In laboratory settings, KLOW 80mg is studied as a combined NSAID-PPI formulation, with research applications spanning COX enzyme pharmacology, prostaglandin biology, and gastrointestinal protection mechanisms. EU and European researchers working with KLOW typically focus on:

• NSAID pharmacology and COX inhibition research — Ketoprofen’s non-selective COX-1/COX-2 inhibition profile makes KLOW a research tool for studying cyclooxygenase enzyme biology, arachidonic acid cascade pharmacology, and the differential effects of COX-1 versus COX-2 inhibition on prostaglandin production in inflammatory and gastric mucosal tissue.
• Prostaglandin biology and inflammation research — studies have used ketoprofen and related propionic acid NSAIDs to examine how COX-mediated prostaglandin synthesis drives inflammatory signalling, pain transduction, and fever responses — with KLOW providing a well-characterised COX inhibitor for these research applications.
• Gastrointestinal protection research — the NSAID-PPI combination model embodied by KLOW is central to research examining how PPI co-administration modifies the gastric injury profile associated with COX-1 inhibition — including studies of gastric mucosal integrity, acid suppression, and the interaction between prostaglandin depletion and acid-driven mucosal damage.
• Proton pump inhibitor pharmacology — Omeprazole’s irreversible H+/K+-ATPase inhibition mechanism makes KLOW relevant to research studying gastric acid secretion biology, parietal cell proton pump pharmacology, and the dose-response relationship between PPI administration and intragastric pH elevation.
• Drug interaction and combination pharmacology research — KLOW provides a model for studying pharmacokinetic and pharmacodynamic interactions between NSAIDs and PPIs — including effects of omeprazole on ketoprofen absorption, metabolism, and gastric bioavailability in combined administration protocols.
• NSAID-associated gastric injury models — ketoprofen’s well-characterised gastric injury profile in pre-clinical models makes KLOW relevant to research studying the mechanisms of NSAID-induced gastric mucosal damage — including prostaglandin depletion, acid back-diffusion, and neutrophil-mediated injury — and the protective effects of acid suppression.
• COX-1 versus COX-2 selectivity research — as a non-selective NSAID, ketoprofen is used as a comparator compound in research examining how COX selectivity influences the balance between anti-inflammatory efficacy and gastrointestinal safety — a central question in NSAID pharmacology research.
• Arachidonic acid cascade research — ketoprofen’s inhibition of both COX isoforms makes KLOW a research tool for studying the full spectrum of arachidonic acid-derived mediators — including prostaglandins, thromboxanes, and prostacyclins — and their roles in inflammatory and homeostatic biology.
• Analgesic mechanism research — studies examining peripheral and central prostaglandin-mediated pain sensitisation use ketoprofen as a reference COX inhibitor for investigating analgesic mechanisms at spinal and peripheral nociceptor sites.

All research applications are for in vitro and pre-clinical use only.

What Do Studies Say About KLOW 80mg Components?

The individual components of KLOW — Ketoprofen and Omeprazole — each have extensive, well-characterised research literatures, with a growing body of combination pharmacology research examining their co-administration profile.

Ketoprofen COX inhibition: Ketoprofen is one of the most extensively studied propionic acid NSAIDs in the pre-clinical and clinical literature — with studies comprehensively characterising its dual COX-1/COX-2 inhibitory activity, its potency relative to other NSAIDs in prostaglandin synthesis inhibition assays, and its anti-inflammatory and analgesic effects in standard pre-clinical inflammatory models including carrageenan paw oedema, adjuvant arthritis, and writhing assays.

Gastrointestinal NSAID injury mechanisms: Research has established that NSAID-associated gastric injury involves two complementary mechanisms — topical irritant effects of acidic NSAID molecules on gastric mucosa, and systemic suppression of COX-1-derived gastroprotective prostaglandins (primarily PGE2 and PGI2) that normally maintain mucosal blood flow, bicarbonate secretion, and epithelial integrity. Studies using ketoprofen as the NSAID model have contributed to characterising both mechanisms and their relative contributions to mucosal injury.

Omeprazole PPI pharmacology: Omeprazole’s irreversible inhibition of the gastric H+/K+-ATPase proton pump is among the most comprehensively characterised drug mechanisms in gastrointestinal pharmacology — with studies documenting its dose-dependent acid suppression profile, the covalent nature of its pump inhibition, and its CYP2C19-mediated hepatic metabolism that produces individual variation in acid suppression responses relevant to pharmacokinetic research designs.

NSAID-PPI combination research: Studies examining PPI co-administration in NSAID users have characterised the degree of gastric mucosal protection conferred by acid suppression against NSAID injury — with research establishing that while PPI co-administration substantially reduces NSAID-associated gastric ulcer risk, it provides incomplete protection against small intestinal NSAID injury where acid suppression is not the primary injury mechanism. This distinction has driven continued research into the limits and mechanisms of PPI gastroprotection in NSAID models.

Ketoprofen central nervous system effects: Research has characterised ketoprofen’s ability to cross the blood-brain barrier and inhibit central COX activity — distinguishing it from NSAIDs with poor CNS penetration and making it relevant to research examining spinal and supraspinal prostaglandin-mediated pain sensitisation and central analgesic mechanisms.

Omeprazole drug interaction research: Studies have characterised omeprazole’s CYP2C19 inhibitory activity and its influence on the pharmacokinetics of co-administered drugs metabolised by this enzyme — a pharmacokinetic interaction relevant to combination formulation research and drug-drug interaction studies using the KLOW model.

KLOW vs Related NSAID and Gastrointestinal Research Compounds

Compound	Type	COX Profile	GI Protection	Key Research Distinction
KLOW (Ketoprofen + Omeprazole)	NSAID + PPI combination	Non-selective COX-1/COX-2	PPI co-administration model	Combined NSAID-GI protection pharmacology research
Ketoprofen alone	Propionic acid NSAID	Non-selective	None	Reference non-selective COX inhibitor
Ibuprofen	Propionic acid NSAID	Non-selective	None	High-volume reference NSAID, COX pharmacology
Celecoxib	Coxib NSAID	COX-2 selective	Reduced GI risk	Selective COX-2 inhibition research
Indomethacin	Indole acetic acid NSAID	Non-selective — potent	None	Potent reference NSAID, gastric injury model induction
Omeprazole alone	Proton pump inhibitor	None	H+/K+-ATPase inhibition	Reference PPI, acid suppression biology
Lansoprazole	Proton pump inhibitor	None	H+/K+-ATPase inhibition	Comparative PPI pharmacology research

Buying KLOW 80mg in Europe — What’s Included

Every order of KLOW 80mg dispatched to EU and European research institutions includes:

• Batch-Specific Certificate of Analysis (CoA)
• Analytical Purity Testing Documentation
• Formulation Composition Confirmation
• Reconstitution / Handling Protocol
• Technical Research Support

Frequently Asked Questions — KLOW 80mg EU

Can I Buy KLOW 80mg in the EU and Europe?

Yes. We supply research-grade KLOW 80mg with fast tracked international dispatch to all EU member states and wider European destinations. All orders include full batch documentation and are packaged to maintain formulation integrity throughout transit. KLOW is supplied strictly for laboratory research use only.

What is Ketoprofen and How Does it Work as an NSAID?

Ketoprofen is a propionic acid class non-steroidal anti-inflammatory drug that inhibits both COX-1 and COX-2 isoforms of the cyclooxygenase enzyme — blocking the conversion of arachidonic acid to prostaglandins, thromboxanes, and prostacyclins. Its non-selective inhibition profile produces potent anti-inflammatory and analgesic effects through prostaglandin synthesis suppression in inflamed tissue, while simultaneously reducing the gastroprotective prostaglandins normally produced by constitutive COX-1 activity in gastric mucosa — the mechanistic basis for NSAID-associated gastric injury that makes PPI co-administration research relevant.

What is Omeprazole and How Does it Protect the Gastric Mucosa?

Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+-ATPase enzyme in gastric parietal cells — the final common pathway of gastric acid secretion. By blocking acid production at its source, omeprazole raises intragastric pH and reduces the acid-mediated component of NSAID-associated gastric mucosal injury. Its inclusion in the KLOW combination reflects the established research and clinical strategy of PPI co-administration to mitigate NSAID gastric injury risk — providing a model for studying the pharmacodynamic interaction between acid suppression and NSAID-mediated prostaglandin depletion in gastrointestinal protection research.

What is the Difference Between COX-1 and COX-2 Inhibition in NSAID Research?

COX-1 is a constitutively expressed isoform present in most tissues — including gastric mucosa, platelets, and kidney — where it produces prostaglandins with homeostatic functions including gastric mucosal protection, platelet aggregation, and renal blood flow regulation. COX-2 is an inducible isoform upregulated at sites of inflammation — producing the prostaglandins that drive inflammatory pain and fever. Non-selective NSAIDs like ketoprofen inhibit both isoforms — producing anti-inflammatory effects through COX-2 inhibition but also gastric and platelet effects through COX-1 inhibition. This distinction is central to NSAID pharmacology research and drives studies examining selective COX-2 inhibitors versus non-selective NSAIDs in gastrointestinal safety research.

Why is NSAID-PPI Co-Administration an Important Research Model?

NSAID-associated gastrointestinal injury is one of the most studied adverse drug effect mechanisms in pharmacology — with research establishing that COX-1-mediated gastroprotective prostaglandin suppression creates a vulnerability to acid-driven mucosal damage that PPI co-administration partially mitigates. The KLOW combination provides a defined, characterised research model for studying this interaction — enabling investigation of the mechanistic boundaries of PPI gastroprotection, the relative contributions of acid suppression versus prostaglandin replacement strategies, and the pharmacokinetic interactions between NSAID and PPI components in combined administration protocols.

How Should KLOW 80mg Be Handled in Laboratory Settings?

KLOW 80mg is supplied as an oral tablet formulation. For in vitro research applications requiring solution preparation, tablets should be handled according to standard pharmaceutical research protocols — with appropriate solvent selection based on the research application. Store at room temperature in a dry environment protected from light and moisture. Standard laboratory safety protocols for handling pharmaceutical research compounds apply.

How Quickly is KLOW 80mg Delivered to Europe?

Orders are dispatched promptly via tracked international courier. Delivery to EU and European destinations typically takes 3–7 working days depending on location, with packaging designed to maintain formulation integrity throughout transit.

Product Specifications

Parameter	Detail
Type	Combination NSAID + PPI Oral Research Tablet
Active Components	Ketoprofen (NSAID) + Omeprazole (PPI)
Dose	80mg per tablet
COX Profile	Non-selective COX-1 / COX-2 inhibition (Ketoprofen)
GI Mechanism	H+/K+-ATPase inhibition — acid suppression (Omeprazole)
Primary Research Interest	NSAID-PPI combination pharmacology, GI protection research
Form	Oral Tablet
Storage	Room temperature, dry, protected from light
Intended Use	Research use only

Research Disclaimer

KLOW 80mg is supplied exclusively for legitimate scientific research conducted within licensed laboratory environments. This product is not approved for human consumption, self-administration, or any therapeutic, clinical, or veterinary application. It must be handled solely by qualified researchers in compliance with applicable EU regulations, national legislation, and institutional ethics guidelines. By purchasing, you confirm this compound will be used exclusively for approved in vitro or pre-clinical research purposes.